ALMS vs DNA

Head-to-Head Stock Analysis & Investment Rating

Last Updated: Nov 12, 2026

ALMS

39.8
AI Score
VS
DNA Wins

DNA

48.2
AI Score

Investment Advisor Scores

ALMS

40score
Recommendation
AVOID NEW MONEY

DNA

48score
Recommendation
HOLD

AI Analyst Insights

Detailed Metrics Comparison

Metric ALMS DNA Winner
Forward P/E 0 0 Tie
PEG Ratio 0 0 Tie
Revenue Growth -37.7% -5.7% DNA
Earnings Growth 0.0% 0.0% Tie
Tradestie Score 39.8/100 48.2/100 DNA
Profit Margin 0.0% -192.0% ALMS
Beta 1.00 1.00 Tie
AI Recommendation AVOID NEW MONEY HOLD DNA

Relative Price Performance (Last 90 Days)

ALMS 1M: +0.9% · 3M: -72.9% DNA 1M: -12.8% · 3M: +41.6%

Current Technical Phase

ALMS

Markdown
Sell / avoid

Price below a falling SMA50 (slope -48.4%), weak momentum, RSI 43

RSI (14): 43.3 · Price: $6.62

DNA

Neutral
Hold

Mixed signals - no dominant trend phase, RSI 47

RSI (14): 47.1 · Price: $10.25

Fundamentals Snapshot

Metric ALMS DNA
Market Cap — —
Forward P/E -2.3 -3.5
Trailing P/E — —
Revenue (TTM) — —
Revenue Growth -0.4% -0.1%
Gross Margin 1.0% 0.7%
Operating Margin -64.4% -1.6%
EPS -3.77 -4.24
Dividend Yield — —

Frequently Asked Questions

Based on our detailed analysis, DNA is currently the stronger investment candidate based on our comprehensive scoring model.

We analyze revenue and earnings growth rates in the "Growth" section above. Generally, the company with higher year-over-year revenue and EPS growth is fostering better expansion. Check the table above for the specific growth percentages.

Valuation is determined by metrics like the P/E Ratio and PEG Ratio. A lower P/E typically suggests a stock is cheaper relative to its earnings. Refer to the "Valuation" section in our comparison table to see which stock currently trades at a more attractive multiple.